# A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

Source: https://onco.cc/trials/nct06012435/  
OnCo record `nct06012435` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Docetaxel in non-small-cell lung cancer, run by Seagen, a wholly owned subsidiary of Pfizer, active and no longer recruiting.

## Summary

A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer is a phase 3 interventional study registered as NCT06012435 by Seagen, a wholly owned subsidiary of Pfizer, with 762 participants enrolled, started 2024-02-21 and due to reach its primary completion in 2026-05-18. Interventions recorded: sigvotatug vedotin and docetaxel.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06012435
- Phase: 3
- Setting: A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY TO EVALUATE SIGVOTATUG VEDOTIN COMPARED WITH DOCETAXEL IN ADULT PARTICIPANTS WITH PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER (BE6A LUNG-01)
- Sponsor: Seagen, a wholly owned subsidiary of Pfizer
- Enrolled: 762

## Sources

- ClinicalTrials.gov NCT06012435: https://clinicaltrials.gov/study/NCT06012435

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/)

---
JSON: https://onco.cc/api/v1/entities/nct06012435.json